Bank of New York Mellon’s BridgeBio Pharma BBIO Stock Holding History

Bank of New York Mellon’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41M	Sell	550,968 -26,315	-5%	-$1.84M	0.01%	1197
2026 Q1	$42.9M	Sell	577,283 -19,120	-3%	-$1.39M	0.01%	1087
2025 Q4	$45.6M	Sell	596,403 -331,370	-36%	-$21.8M	0.01%	1060
2025 Q3	$48.2M	Buy	927,773 +379,566	+69%	+$18.5M	0.01%	1033
2025 Q2	$23.7M	Buy	548,207 +64,532	+13%	+$2.35M	﹤0.01%	1426
2025 Q1	$16.7M	Sell	483,675 -17,456	-3%	-$589K	﹤0.01%	1590
2024 Q4	$13.8M	Sell	501,131 -6,939	-1%	-$179K	﹤0.01%	1765
2024 Q3	$12.9M	Sell	508,070 -116,699	-19%	-$3.06M	﹤0.01%	1805
2024 Q2	$15.8M	Buy	624,769 +112,678	+22%	+$3.08M	﹤0.01%	1719
2024 Q1	$15.8M	Sell	512,091 -31,928	-6%	-$1.09M	﹤0.01%	1710
2023 Q4	$22M	Buy	544,019 +80,242	+17%	+$2.41M	﹤0.01%	1541
2023 Q3	$12.2M	Sell	463,777 -5,493	-1%	-$156K	﹤0.01%	1824
2023 Q2	$8.07M	Buy	469,270 +474	+0.1%	+$7.13K	﹤0.01%	2057
2023 Q1	$7.77M	Buy	468,796 +33,634	+8%	+$392K	﹤0.01%	2059
2022 Q4	$3.32M	Buy	435,162 +5,252	+1%	+$50.3K	﹤0.01%	2569
2022 Q3	$4.27M	Buy	429,910 +53,477	+14%	+$556K	﹤0.01%	2370
2022 Q2	$3.42M	Sell	376,433 -126,280	-25%	-$1.06M	﹤0.01%	2526
2022 Q1	$5.1M	Buy	502,713 +15,368	+3%	+$158K	﹤0.01%	2410
2021 Q4	$8.13M	Buy	487,345 +12,641	+3%	+$535K	﹤0.01%	2213
2021 Q3	$22.2M	Buy	474,704 +21,608	+5%	+$1.16M	﹤0.01%	1667
2021 Q2	$27.6M	Buy	453,096 +84,707	+23%	+$4.84M	0.01%	1549
2021 Q1	$22.7M	Buy	368,389 +96,607	+36%	+$6.32M	﹤0.01%	1637
2020 Q4	$19.3M	Buy	271,782 +23,846	+10%	+$1.15M	﹤0.01%	1657
2020 Q3	$9.3M	Buy	247,936 +16,534	+7%	+$520K	﹤0.01%	1891
2020 Q2	$7.54M	Buy	231,402 +6,952	+3%	+$212K	﹤0.01%	1988
2020 Q1	$6.51M	Buy	224,450 +144,812	+182%	+$4.49M	﹤0.01%	1935
2019 Q4	$2.79M	Buy	79,638 +19,265	+32%	+$534K	﹤0.01%	2625
2019 Q3	$1.3M	Buy	+60,373	New	+$1.67M	﹤0.01%	3011

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bank of New York Mellon's BBIO Position: Q2 2026 in Review

Bank of New York Mellon reduced its BridgeBio Pharma (BBIO) stake by 4.6% in Q2 2026, selling an estimated $1.84M and leaving 550,968 shares worth $41M. The position accounts for 0.01% of the portfolio, ranked #1197.

Bank of New York Mellon first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $48.2M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Bank of New York Mellon held 550,968 shares of BridgeBio Pharma worth $41M as of Q2 2026.
Bank of New York Mellon sold 26,315 BridgeBio Pharma shares in Q2 2026, an estimated $1.84M.
BridgeBio Pharma made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1197 holding.
Bank of New York Mellon first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
Bank of New York Mellon's BridgeBio Pharma position peaked at $48.2M in Q3 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.